These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 7695248

  • 21. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM, Que YA, Vouillamoz J, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [Abstract] [Full Text] [Related]

  • 22. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
    Visalli MA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881
    [Abstract] [Full Text] [Related]

  • 23. Penicillin therapy for treatment of experimental endocarditis caused by viridans streptococci in animals.
    Wilson WR, Zak O, Sande MA.
    J Infect Dis; 1985 Jun; 151(6):1028-33. PubMed ID: 3846608
    [Abstract] [Full Text] [Related]

  • 24. Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae.
    Tomizawa H, Tateda K, Miyazaki S, Yamaguchi K.
    J Antimicrob Chemother; 1998 Jan; 41(1):103-6. PubMed ID: 9511043
    [Abstract] [Full Text] [Related]

  • 25. Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.
    Pankuch GA, Lichtenberger C, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1653-6. PubMed ID: 8807057
    [Abstract] [Full Text] [Related]

  • 26. Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with clinafloxacin and penicillin.
    Zaman MM, Landman D, Burney S, Quale JM.
    J Antimicrob Chemother; 1996 Jan; 37(1):127-32. PubMed ID: 8647753
    [Abstract] [Full Text] [Related]

  • 27. Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits.
    Vazquez J, Perri MB, Thal LA, Donabedian SA, Zervos MJ.
    J Antimicrob Chemother; 1993 Nov; 32(5):715-21. PubMed ID: 8125836
    [Abstract] [Full Text] [Related]

  • 28. Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.
    Anguita-Alonso P, Rouse MS, Piper KE, Steckelberg JM, Patel R.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1263-7. PubMed ID: 16569838
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection.
    Crémieux AC, Mghir AS, Bleton R, Manteau M, Belmatoug N, Massias L, Garry L, Sales N, Mazière B, Carbon C.
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2111-6. PubMed ID: 8878590
    [Abstract] [Full Text] [Related]

  • 30. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH, Jones RN, Johnson DM, Deinhart JA, Schentag JJ.
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [Abstract] [Full Text] [Related]

  • 31. RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci.
    L'Hériteau F, Entenza JM, Lacassin F, Leport C, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1425-9. PubMed ID: 7492079
    [Abstract] [Full Text] [Related]

  • 32. Ceftriaxone sodium therapy of penicillin G-susceptible streptococcal endocarditis.
    Wilson WR.
    JAMA; 1992 Jan 08; 267(2):279-80. PubMed ID: 1727528
    [No Abstract] [Full Text] [Related]

  • 33. Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis.
    Saleh-Mghir A, Cremieux AC, Vallois JM, Muffat-Joly M, Devine C, Carbon C.
    Antimicrob Agents Chemother; 1992 Nov 08; 36(11):2403-7. PubMed ID: 1489184
    [Abstract] [Full Text] [Related]

  • 34. Efficacy of beta-lactams against experimental pneumococcal endocarditis caused by strains with different susceptibilities to penicillin.
    Pichardo C, Docobo-Pérez F, Pachón-Ibáñez ME, Jiménez-Mejías ME, García-Curiel A, Caballero-Granado FJ, Moreno-Maqueda I, Pachón J.
    J Antimicrob Chemother; 2005 Oct 08; 56(4):732-7. PubMed ID: 16150863
    [Abstract] [Full Text] [Related]

  • 35. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1992 Apr 08; 36(4):856-9. PubMed ID: 1323956
    [Abstract] [Full Text] [Related]

  • 36. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP, Mouton JW, den Hollander JG, van den Braak N, Verbrugh HA.
    Antimicrob Agents Chemother; 1997 May 08; 41(5):1146-9. PubMed ID: 9145886
    [Abstract] [Full Text] [Related]

  • 37. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.
    Pfaller MA, Jones RN, Marshall SA, Edmond MB, Wenzel RP.
    Diagn Microbiol Infect Dis; 1997 Dec 08; 29(4):259-63. PubMed ID: 9458983
    [Abstract] [Full Text] [Related]

  • 38. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Cagni A, Chuard C, Vaudaux PE, Schrenzel J, Lew DP.
    Antimicrob Agents Chemother; 1995 Aug 08; 39(8):1655-60. PubMed ID: 7486895
    [Abstract] [Full Text] [Related]

  • 39. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
    Visalli MA, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 1996 Jan 08; 37(1):77-84. PubMed ID: 8647777
    [Abstract] [Full Text] [Related]

  • 40. Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis.
    Francioli PB, Glauser MP.
    Antimicrob Agents Chemother; 1993 Feb 08; 37(2):207-12. PubMed ID: 8452350
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.